{"id":11611,"date":"2026-10-26T19:59:30","date_gmt":"2026-10-26T16:59:30","guid":{"rendered":"https:\/\/www.ortaakarsu.net\/?p=11611"},"modified":"2026-10-26T19:59:30","modified_gmt":"2026-10-26T16:59:30","slug":"paxlovid-ilac-etkilesimleri-kontrol-listesi","status":"publish","type":"post","link":"https:\/\/www.ortaakarsu.net\/?p=11611","title":{"rendered":"Paxlovid ve Di\u011fer \u0130la\u00e7lar: Tedavi \u00d6ncesi Etkile\u015fim Kontrol Listesi"},"content":{"rendered":"<p><a href=\"https:\/\/www.ortaakarsu.net\/?ism_drug=paxlovid-150-mg-100-mg-film-kapli-tablet\">Paxlovid<\/a>, nirmatrelvir ile ritonavir i\u00e7eren bir COVID-19 tedavisidir. Ritonavir di\u011fer ila\u00e7lar\u0131n v\u00fccutta i\u015flenmesini de\u011fi\u015ftirebildi\u011fi i\u00e7in, k\u0131sa bir tedavi s\u00fcresi bile \u00f6nemli etkile\u015fimler olu\u015fturabilir. Karar yaln\u0131zca \u201cila\u00e7lar\u0131 farkl\u0131 saatlerde alabilir miyim?\u201d sorusuyla verilemez. Hekimin t\u00fcm ila\u00e7 listesini ve yak\u0131n zamanda tamamlanan tedavileri g\u00f6rmesi gerekir. Bu rehber, re\u00e7ete g\u00f6r\u00fc\u015fmesine haz\u0131rlanmak i\u00e7indir; ki\u015fisel tedavi plan\u0131n\u0131 belirlemez. <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/paxlovid\">Kaynak: EMA de\u011ferlendirmesi<\/a>.<\/p>\n<h2>G\u00f6r\u00fc\u015fmeye giderken hangi bilgileri haz\u0131rlamal\u0131y\u0131m?<\/h2>\n<p>\u0130la\u00e7 ad\u0131, etken madde, kullan\u0131lan miktar, kullan\u0131m s\u0131kl\u0131\u011f\u0131 ve son al\u0131nan zaman\u0131 ayn\u0131 listede bulundurun. D\u00fczenli ila\u00e7lar\u0131n yan\u0131nda gerekti\u011finde al\u0131nan uyku ilac\u0131, a\u011fr\u0131 kesici, \u00f6ks\u00fcr\u00fck \u00fcr\u00fcn\u00fc, vitamin, bitkisel \u00fcr\u00fcn ve do\u011fum kontrol y\u00f6ntemini de ekleyin. Bir ilac\u0131n kutusu yoksa foto\u011fraf\u0131 veya eczane kayd\u0131, yaln\u0131zca \u201ctansiyon ilac\u0131\u201d demekten daha a\u00e7\u0131klay\u0131c\u0131d\u0131r. Ba\u015fka bir hekimden yeni re\u00e7ete al\u0131nd\u0131\u011f\u0131nda bu liste de g\u00fcncellenmelidir.<\/p>\n<p>B\u00f6brek hastal\u0131\u011f\u0131, diyaliz, karaci\u011fer hastal\u0131\u011f\u0131, gebelik olas\u0131l\u0131\u011f\u0131 ve emzirme ayr\u0131ca bildirilmelidir. B\u00f6brek i\u015flevi, Paxlovid i\u00e7in se\u00e7ilecek uygulama plan\u0131n\u0131 etkileyebilir; kutudaki tablet say\u0131s\u0131 tek ba\u015f\u0131na ki\u015fisel kullan\u0131m talimat\u0131 de\u011fildir. Yeni bir ila\u00e7 eklenmeden \u00f6nce ayn\u0131 kontrol\u00fcn tekrar yap\u0131lmas\u0131 gerekir. <a href=\"https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?Section=PPI&amp;id=19599\">Kaynak: FDA onayl\u0131 hasta bilgisi<\/a>.<\/p>\n<h2>Hangi ila\u00e7 gruplar\u0131 \u00f6zellikle \u00f6nemlidir?<\/h2>\n<ul>\n<li><strong>Kolesterol ila\u00e7lar\u0131:<\/strong> Simvastatin ve lovastatin birlikte kullan\u0131m a\u00e7\u0131s\u0131ndan kontrendikedir; kas hasar\u0131 riski \u00f6nemlidir. Atorvastatin veya rosuvastatin i\u00e7in de ayr\u0131ca de\u011ferlendirme gerekir. B\u00fct\u00fcn statinlere ayn\u0131 karar uygulanmaz. <a href=\"https:\/\/www.ortaakarsu.net\/?ism_drug=zocor-20-mg\">Simvastatin<\/a> ile <a href=\"https:\/\/www.ortaakarsu.net\/?ism_drug=lipitor-20-mg\">atorvastatin<\/a> kutular\u0131n\u0131 ayn\u0131 ba\u015fl\u0131k alt\u0131nda bildirin.<\/li>\n<li><strong>Prostat ila\u00e7lar\u0131:<\/strong> <a href=\"https:\/\/www.ortaakarsu.net\/?ism_drug=xatral-xl-10-mg-denetimli-salimli-tablet\">Alfuzosin<\/a> d\u00fczeyi artabilir ve ciddi tansiyon d\u00fc\u015fmesi geli\u015febilir; Paxlovid ile birlikte kullan\u0131m\u0131 kontrendikedir. Benzer ama\u00e7la kullan\u0131lan ila\u00e7lar\u0131n isimleri birbirinin yerine ge\u00e7mez.<\/li>\n<li><strong>Epilepsi ila\u00e7lar\u0131 ve bitkisel \u00fcr\u00fcnler:<\/strong> Karbamazepin, fenitoin, fenobarbital, primidon ve sar\u0131 kantaronla Paxlovid birlikte kullan\u0131m\u0131 kontrendikedir; antiviral d\u00fczeyi ve etkisi azalabilir. Bu ila\u00e7lar\u0131 kendiniz b\u0131rakmay\u0131n; uygun COVID-19 tedavisini hekim belirler. Etkile\u015fim yaln\u0131zca yan etki art\u0131\u015f\u0131 anlam\u0131na gelmez; antiviral tedavinin etkisi de azalabilir.<\/li>\n<\/ul>\n<p>Bu \u00f6rnekler tam bir yasakl\u0131 ila\u00e7 listesi de\u011fildir. Her \u00fcr\u00fcn\u00fcn g\u00fcncel bilgisi ayr\u0131 kontrol edilir. <a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/paxlovid-epar-product-information_en.pdf\">Kaynak: EMA \u00fcr\u00fcn bilgisi, 4.3\u20134.5<\/a>. Kas belirtileri hakk\u0131nda <a href=\"https:\/\/www.ortaakarsu.net\/?p=11492\">statin g\u00fcvenli\u011fi rehberi<\/a> de yard\u0131mc\u0131 olabilir.<\/p>\n<h2>Kan suland\u0131r\u0131c\u0131 kullan\u0131yorum: Hepsi i\u00e7in ayn\u0131 risk mi var?<\/h2>\n<p>Hay\u0131r. Ritonavir, apiksaban ve rivaroksaban gibi baz\u0131 ila\u00e7lar\u0131n kan d\u00fczeyini ve kanama riskini art\u0131rabilir. Varfarin kullananlarda ise etki farkl\u0131 y\u00f6nde de\u011fi\u015febilece\u011finden INR izlemi \u00f6nemlidir. \u0130la\u00e7 ad\u0131 kadar kullan\u0131m nedeni ve b\u00f6brek i\u015flevi de de\u011ferlendirmeyi etkiler. <a href=\"https:\/\/www.ortaakarsu.net\/?ism_drug=coumadin-5-mg\">Coumadin<\/a> kullan\u0131yorsan\u0131z son INR sonucunu ve bir sonraki kontrol\u00fcn zaman\u0131n\u0131 g\u00f6r\u00fc\u015fmeye g\u00f6t\u00fcr\u00fcn. Kendi kendine yap\u0131lan bir ara verme, kanama riskinin yan\u0131nda p\u0131ht\u0131 riskini de g\u00fcndeme getirir; de\u011fi\u015fiklik ve takip plan\u0131n\u0131 tedaviyi y\u00fcr\u00fcten ekip olu\u015fturur. <a href=\"https:\/\/www.medicines.org.uk\/emc\/product\/13145\/smpc\">Kaynak: Paxlovid SmPC, 4.5<\/a>. Re\u00e7etesiz a\u011fr\u0131 kesiciler de <a href=\"https:\/\/www.ortaakarsu.net\/?p=11465\">kan suland\u0131r\u0131c\u0131 rehberindeki<\/a> kontrol listesine eklenmelidir.<\/p>\n<h2>Rifampisini yeni bitirdim; yine de bildirmeli miyim?<\/h2>\n<p>Evet. <a href=\"https:\/\/www.ortaakarsu.net\/?ism_drug=rifcap-300-mg-kapsul\">Rifampisin<\/a> g\u00fc\u00e7l\u00fc bir enzim uyar\u0131c\u0131s\u0131d\u0131r. Bu etki son tabletten hemen sonra kaybolmaz; Paxlovid rifampisin kesilir kesilmez ba\u015flat\u0131lamaz. \u201c\u0130ki ilac\u0131 ayn\u0131 g\u00fcn alm\u0131yorum\u201d bilgisi g\u00fcvenli\u011fi g\u00f6stermeye yetmez. \u0130lac\u0131n neden verildi\u011fini, hangi tarihte ba\u015fland\u0131\u011f\u0131n\u0131 ve son kullan\u0131m tarihini bildirin. Uygun antiviral se\u00e7imi ve zamanlamas\u0131, COVID-19 tedavisinin erken ba\u015flanmas\u0131 gere\u011fiyle birlikte de\u011ferlendirilir. Sabit bir bekleme s\u00fcresini herkes i\u00e7in ge\u00e7erli kabul etmek do\u011fru de\u011fildir. <a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/paxlovid-epar-product-information_en.pdf\">Kaynak: EMA \u00fcr\u00fcn bilgisi, 4.3\u20134.5<\/a>.<\/p>\n<h2>Nakil ilac\u0131 kullan\u0131rken neden \u00f6zel bir plan gerekir?<\/h2>\n<p><a href=\"https:\/\/www.ortaakarsu.net\/?ism_drug=prograf-1-mg-sert-jelatin-kapsul\">Takrolimus<\/a> ve <a href=\"https:\/\/www.ortaakarsu.net\/?ism_drug=sandimmun-neoral-100-mg-yumusak-jelatin-kapsul\">siklosporin<\/a> d\u00fczeyleri h\u0131zla toksik seviyelere \u00e7\u0131kabilir. EMA, ya\u015fam\u0131 tehdit eden ve \u00f6l\u00fcmc\u00fcl bildirimler nedeniyle yak\u0131n ve d\u00fczenli ila\u00e7 d\u00fczeyi izlemini \u00f6zellikle vurgular. Bu izlem Paxlovid s\u0131ras\u0131nda ve tedavi sonras\u0131nda gerekir. Nakil ekibine ula\u015f\u0131lmadan, yaln\u0131zca ila\u00e7 saatlerini ay\u0131rmaya dayanan bir plan yeterli de\u011fildir. G\u00f6r\u00fc\u015fmede \u201cKan d\u00fczeyi nerede \u00f6l\u00e7\u00fclecek, sonucu kim de\u011ferlendirecek, tedavi sonras\u0131 kontrol ne zaman?\u201d sorular\u0131n\u0131 netle\u015ftirin. Ayr\u0131nt\u0131lar i\u00e7in <a href=\"https:\/\/www.ortaakarsu.net\/?p=11607\">nakil ila\u00e7lar\u0131 etkile\u015fim rehberine<\/a> bakabilirsiniz. <a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/dhpc\/direct-healthcare-professional-communication-dhpc-paxlovid-nirmatrelvir-ritonavir-reminder-life-threatening-fatal-drug-drug-interactions-certain-immunosuppressants-including-tacrolimus_en.pdf\">Kaynak: EMA g\u00fcvenlik bildirimi<\/a>.<\/p>\n<h2>Hepatit C tedavisi veya mide koruyucu kullan\u0131yorsam?<\/h2>\n<p><a href=\"https:\/\/www.ortaakarsu.net\/?ism_drug=epclusa-400-mg-100-mg-film-kapli-tablet\">Epclusa<\/a> gibi antiviral tedaviler de tam ila\u00e7 listesine yaz\u0131lmal\u0131d\u0131r. Epclusa&#8217;n\u0131n kendi etkile\u015fimleri aras\u0131nda rifampisinle etkinli\u011fin azalmas\u0131, amiodaronla ciddi yava\u015f kalp at\u0131m\u0131 ve asit azalt\u0131c\u0131larla velpatasvir emiliminin azalmas\u0131 bulunur. Bu nedenle COVID-19 s\u0131ras\u0131nda eklenen ila\u00e7lar kadar \u00f6nceden kullan\u0131lan <a href=\"https:\/\/www.ortaakarsu.net\/?ism_drug=losec-20-mg\">omeprazol<\/a> ve <a href=\"https:\/\/www.ortaakarsu.net\/?ism_drug=cordarone-200-mg\">amiodaron<\/a> da \u00f6nemlidir. Bu paragraf Paxlovid ile Epclusa&#8217;n\u0131n otomatik olarak yasakl\u0131 bir \u00e7ift oldu\u011fu anlam\u0131na gelmez; e\u015fzamanl\u0131 b\u00fct\u00fcn tedavi de\u011ferlendirilir. <a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/208341s019lbl.pdf\">Kaynak: FDA Epclusa \u00fcr\u00fcn bilgisi<\/a>. Mide koruyucular\u0131n\u0131n farkl\u0131 etkile\u015fimleri i\u00e7in <a href=\"https:\/\/www.ortaakarsu.net\/?p=11493\">ilgili rehbere<\/a> bak\u0131n.<\/p>\n<h2>Hangi belirtilerde beklememeliyim?<\/h2>\n<p>Dudak, dil veya y\u00fczde \u015fi\u015fme; nefes alma ya da yutma g\u00fc\u00e7l\u00fc\u011f\u00fc; kabarc\u0131kl\u0131 veya soyulan yayg\u0131n d\u00f6k\u00fcnt\u00fc acil yard\u0131m gerektirir. Sar\u0131l\u0131k, koyu idrar ve belirgin kar\u0131n a\u011fr\u0131s\u0131 i\u00e7in gecikmeden t\u0131bbi de\u011ferlendirme al\u0131nmal\u0131d\u0131r. Tat de\u011fi\u015fikli\u011fi ve ishal bildirilen yan etkilerdir; \u015fiddeti, s\u00fcresi ve beraberindeki bulgular hekim veya eczac\u0131yla de\u011ferlendirilir. Belirtiyi yaln\u0131zca \u201cCOVID&#8217;dendir\u201d ya da \u201cila\u00e7tand\u0131r\u201d diye s\u0131n\u0131fland\u0131rmak yerine ba\u015flad\u0131\u011f\u0131 zaman\u0131 ve ila\u00e7larla ili\u015fkisini kaydedin. <a href=\"https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?Section=PPI&amp;id=19599\">Kaynak: FDA onayl\u0131 hasta bilgisi<\/a>.<\/p>\n<hr>\n<p><strong>Kaynak kontrol\u00fc:<\/strong> <time datetime=\"2026-10-26\">26 Ekim 2026<\/time>. Bu i\u00e7erik yapay zek\u00e2 destekli bir kaynak \u00f6zetidir; hekim veya eczac\u0131 taraf\u0131ndan klinik inceleme yap\u0131ld\u0131\u011f\u0131 anlam\u0131na gelmez. Ki\u015fisel tedavi plan\u0131 de\u011fildir. Yabanc\u0131 \u00fcr\u00fcn belgelerindeki etken madde riskleri, T\u00fcrkiye&#8217;deki \u00fcr\u00fcn\u00fcn g\u00fcncel K\u00dcB ve kullanma talimat\u0131yla birlikte de\u011ferlendirilmelidir.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paxlovid \u00f6ncesinde hangi ila\u00e7lar\u0131n \u00f6zellikle bildirilmesi gerekir? Statinler, kan suland\u0131r\u0131c\u0131lar, rifampisin, prostat ve nakil ila\u00e7lar\u0131 i\u00e7in kaynakl\u0131 kontrol listesi.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-11611","post","type-post","status-publish","format-standard","hentry","category-genel"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/11611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11611"}],"version-history":[{"count":1,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/11611\/revisions"}],"predecessor-version":[{"id":11620,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/11611\/revisions\/11620"}],"wp:attachment":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}